CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

CIViC Evidence Items

191 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline
BClinical — prospective trial or retrospective cohort study
CCase study — single case report or small case series
DPreclinical — in vitro or animal model data
EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

PredictiveDiagnosticPrognosticFunctionalPredispos.Oncogenic
BCR::ABL132311
BRAF18642621
EGFR2481232
EML4::ALK64
ERBB21422
FLT355221
KIT10237
KRAS1594244
PIK3CA156164
PTEN5313121
TP5352401002
VHL52363515
Predictive:Links a variant to treatment response or resistance
Diagnostic:Supports or refutes a specific disease diagnosis
Prognostic:Informs disease progression or clinical outcome
Functional:Characterises the biological effect of a variant
Predisposing:Germline variant associated with cancer predisposition
Oncogenic:Characterises the variant's role in oncogenesis
Clear
LevelGeneVariantTypeDirectionSignificanceDiseaseDrugsSource
DKRASG12CPredictiveSupportsResistanceMultiple MyelomaMelphalanRowley et al., 2000
DKRASG12CPredictiveSupportsResistanceMultiple MyelomaMelphalanHoang et al., 2006
CKRASG12VPredictiveSupportsResistanceLung CancerGefitinibEndoh et al., 2006
BKRASG12SPredictiveSupportsResistanceLung CancerGefitinibEndoh et al., 2006
DKRASG12SPredictiveSupportsResistanceMultiple MyelomaMelphalanRowley et al., 2000
DKRASG12SPredictiveSupportsResistanceMultiple MyelomaMelphalanRowley et al., 2002
DKRASG12SPredictiveSupportsResistanceMultiple MyelomaMelphalanHoang et al., 2006
DKRASG12APredictiveSupportsResistanceColorectal CancerRegorafenib AnhydrousCamaj et al., 2015
BKRASMutationPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaTeprotumumab,ErlotinibRamalingam et al., 2011
DKRASG12VPredictiveSupportsResistanceColorectal CancerRegorafenib AnhydrousCamaj et al., 2015
DKRASG12CPredictiveSupportsResistanceColorectal CancerRegorafenib AnhydrousCamaj et al., 2015
DKRASG12SPredictiveSupportsResistanceColorectal CancerRegorafenib AnhydrousCamaj et al., 2015
BKRASExon 2 MutationPrognosticDoes Not SupportPoor OutcomeRectum CancerHe et al., 2009
EKRASMutationPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaImmune Checkpoint InhibitorLi et al., 2017
BKRASMutationPredictiveSupportsResistanceMelanomaDabrafenib,VemurafenibShi et al., 2014
CKRASG13VPredictiveSupportsResistanceColorectal CancerCetuximab,PanitumumabSartore-Bianchi et al., 2009
CKRASG12SPredictiveSupportsResistanceColorectal CancerPanitumumab,CetuximabSartore-Bianchi et al., 2009
CKRASG12DPredictiveSupportsResistanceColorectal CancerPanitumumab,CetuximabSartore-Bianchi et al., 2009
DKRASAmplificationPredictiveSupportsResistanceMelanomaVemurafenibShi et al., 2014
CKRASG12APredictiveSupportsResistanceColorectal CancerPanitumumab,CetuximabSartore-Bianchi et al., 2009
CKRASG13DPredictiveDoes Not SupportResistanceColorectal CancerPanitumumab,CetuximabSartore-Bianchi et al., 2009
CKRASG13DPredictiveSupportsResistanceColorectal CancerPanitumumab,CetuximabSartore-Bianchi et al., 2009
CKRASG12VPredictiveSupportsResistanceColorectal CancerPanitumumab,CetuximabSartore-Bianchi et al., 2009
DKRASWildtypePredictiveDoes Not SupportResistanceColorectal CancerRegorafenib AnhydrousCamaj et al., 2015
BKRASExon 2 MutationPredictiveDoes Not SupportSensitivity/ResponseColorectal CancerRegorafenib AnhydrousSartore-Bianchi et al., 2014
DKRASG12VPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaPalbociclibPuyol et al., 2010
BKRASG12VPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaSelumetinib,DocetaxelJänne et al., 2015
DKRASMutationPredictiveSupportsResistanceColorectal CancerIxazomibChattopadhyay et al., 2015
BKRASExon 2 MutationPredictiveSupportsSensitivity/ResponseColorectal CancerIrinotecan,SelumetinibHochster et al., 2015
DKRASG13DPredictiveSupportsResistanceColorectal CancerRegorafenib AnhydrousCamaj et al., 2015
DKRASG12DPredictiveSupportsResistanceColorectal CancerRegorafenib AnhydrousCamaj et al., 2015
DKRASG12RPredictiveSupportsResistanceColorectal CancerRegorafenib AnhydrousCamaj et al., 2015
CKRASG12VPredictiveSupportsResistanceColorectal CancerPanitumumabAmado et al., 2008
CKRASG12DPredictiveSupportsResistanceColorectal CancerPanitumumabAmado et al., 2008
DKRASG12DPredictiveSupportsResistanceMultiple MyelomaMelphalanRowley et al., 2002
DKRASG12CPredictiveSupportsResistanceMultiple MyelomaMelphalanRowley et al., 2002
CKRASG12RPredictiveSupportsResistanceColorectal CancerPanitumumabAmado et al., 2008
CKRASG12SPredictiveSupportsResistanceColorectal CancerPanitumumabAmado et al., 2008
CKRASQ61HPredictiveSupportsResistanceColorectal CancerCetuximabMisale et al., 2012
DKRASG13DPredictiveSupportsResistanceColorectal CancerCetuximabMisale et al., 2012
BKRASG13DPredictiveSupportsResistanceColorectal CancerCetuximabKaczirek et al., 2015
Page 4 of 4
Previous